Psychotherapy Improves Outcomes for People with Bipolar Disorder

May 3, 2016 · Posted in Current Treatments · Comment 

psychotherapy helps bipolar disorder

Studies have shown that therapy can be helpful for people with bipolar disorder. In a 2016 article in the British Journal of Psychiatry, researchers led by M. Oud described the findings of their systematic review of studies evaluating different types of therapy for bipolar disorder. The research team reviewed the findings of 55 randomized controlled trials of psychotherapeutic interventions that included a total of 6,010 adult participants with bipolar disorder. The team found moderate-quality evidence that psychological interventions reduced relapses following treatment, and that collaborative care reduced hospital admissions for adults with bipolar disorder. Oud and colleagues found lower-quality evidence that group interventions reduced depression relapses following treatment, and that family psychoeducation reduced symptoms of depression and mania.

The reseachers concluded that there is evidence that therapy can be helpful for people with bipolar disorder. Since some of the evidence was of low quality, more research is needed to identify the most effective therapies for different phases of bipolar disorder.

Editor’s Note: The data are clear that therapy is helpful. In particular, one approach worth emulating is that described in an article by Lars V. Kessing and colleagues in the British Journal of Psychiatry in 2013. They found that comprehensive care in an outpatient mood disorder clinic, which included psychotherapy, psychoeducation, mood monitoring, and drug treatment, reduced relapses significantly compared to treatment as usual.

Treating Prenatal Depression Improves Outcomes for Mothers and Babies

May 2, 2016 · Posted in Current Treatments, Risk Factors · Comment 

pregnancy with depressionA recent study confirms that women who are depressed during pregnancy are more likely to experience adverse pregnancy outcomes such as preterm or cesaerean delivery and small or underweight babies. However, antidepressant treatment improved outcomes for pregnant women with depression.

The 2016 study by Kartik K. Venkatesh and colleagues in the journal Obstetrics & Gynecology included 7,267 women who gave birth after at least 20 weeks of pregnancy. About 11% of the women screened positive for depression during their pregnancy. Depressed mothers-to-be were more likely to give birth before 37 weeks and before 32 weeks compared to nondepressed mothers-to-be. The depressed women were also more likely to deliver small babies or babies weighing under 2500g.

About 7% of the women in the study received antidepressant medication. Compared to nondepressed women, the women taking antidepressants did not have greater rates of early delivery or small babies. However, the authors caution that because so few women received antidepressants, the study does not reveal whether antidepressants improve outcomes for depressed pregnant women.

Oxytocin May Reduce PTSD Symptoms

May 2, 2016 · Posted in Potential Treatments · Comment 

nasal sprayThe hormone oxytocin, best known for creating feelings of love and bonding, may help treat post-traumatic stress disorder, since it also reduces anxiety. A study by Saskia B.J. Koch and colleagues that will soon be published in the journal Neuropsychopharmacology reports that a single intranasal administration of oxytocin (at a dose of 40 IU) reduced anxiety and nervousness more than did placebo among police officers with PTSD.

Oxytocin also improved abnormalities in connectivity of the amygdala. Male participants with PTSD showed reduced connectivity between the right centromedial amygdala and the left ventromedial prefrontal cortex compared to other male participants who had also experienced trauma but did not have PTSD. This deficit was corrected in the men with PTSD after they received a dose of oxytocin. Female participants with PTSD showed greater connectivity between the right basolateral amygdala and the bilateral dorsal anterior cingulate cortex than female participants who had experienced trauma but did not have PTSD. This was also restored to normal following a dose of oxytocin.

These findings suggest that oxytocin can not only reduce subjective feelings of anxiety in people with PTSD, but may also normalize the way fear is expressed in the amygdala.

Inflammation Linked to Bipolar Illness in Young People

May 1, 2016 · Posted in Risk Factors · Comment 

inflammation linked to bipolar disorderThe Course and Outcome of Bipolar Youth study, or COBY, has been collecting information on young people with bipolar disorder and tracking their symptoms into adulthood since 2000. A 2015 study by Benjamin I. Golstein in the Journal of Clinical Psychiatry analyzed COBY data, identifying links between higher than average levels of inflammatory markers measured in the blood and participants’ histories of illness and familial risk factors.

High levels of the inflammatory marker hsCRP were associated with longer duration of illness, substance use disorder, and family history of suicide attempts or completed suicides. High levels of TNF-alpha were linked to suicide attempts, self-injury behaviors, and family history of substance use disorders. IL-6 was also linked to family history of substance use disorders.

There were also links between inflammatory markers and participants’ symptoms over the 6 months leading up to the blood tests. Levels of the inflammatory marker TNF-alpha were linked to the percentage of weeks patients had psychotic symptoms. Levels of IL-6 were associated with percentage of weeks with subthreshold mood symptoms and also with any suicide attempt. Levels of HsCRP were linked to maximum severity of depressive symptoms.

It is possible that targeting the elevated levels of inflammatory markers with anti-inflammatory treatments could improve patients’ response to treatments, but this topic requires further study.

L-methylfolate Improves Depression; More Effective in Overweight Patients with Inflammation

April 29, 2016 · Posted in Current Treatments · Comment 

obese patients

A 2012 study by Geoge I. Papkostas and colleagues found that 15mg/day of the nutritional supplement l-methylfolate calcium (a form of the B vitamin folate that the body can more readily use) improved depression in people who had not responded adequately to treatment with a selective serotonin reuptake inhibitor (SSRI) antidepressant. In a follow-up study by Richard C. Shelton and colleagues published in the Journal of Clinical Psychiatry in 2015, the same researchers further analyzed these data and found that l-methylfolate worked better in patients who were overweight (with body mass indexes (BMIs) of 30 or above) and those who had higher than average levels of inflammation at the beginning of the study. Inflammatory markers linked to greater improvement with l-methylfolate included TNF-alpha, IL-8, high sensitivity CRP, and leptin. In overweight participants, higher than average levels of IL-6 were also linked to more improvement on l-methylfolate.

Vitamin D3 Reduces Symptoms of Bipolar Spectrum Disorders

April 28, 2016 · Posted in Potential Treatments · Comment 

vitamin DVitamin D3 tends to be low in children and adolescents with mania, but supplements may help. In a small open study published in the Journal of Child and Adolescent Psychopharmacology in 2015, Elif M. Sikoglu and colleagues administered 2000 IU of vitamin D3 per day to youth aged 6–17 for eight weeks. Sixteen of the participants had bipolar spectrum disorders (including subthreshold symptoms) and were exhibiting symptoms of mania. Nineteen participants were typically developing youth.

At the beginning of the study, the youth with bipolar spectrum disorders had lower levels of the neurotransmitter GABA in the anterior cingulate cortex than did the typically developing youth. Following the eight weeks of vitamin D3 supplementation, mania and depression symptoms both decreased in the youth with bipolar spectrum disorders, and GABA in the anterior cingulate cortex increased in these participants.

Editor’s Note: GABA dysfunction has been implicated in the manic phase of bipolar disorder. While larger controlled studies of vitamin D supplementation are needed, given the high incidence of vitamin D deficiency in youth in the US, testing and treating these deficiencies is important, especially among kids with symptoms of bipolar illness.

Anti-Viral Treatment Leads to Improvement in Chronic Fatigue/SEID

April 27, 2016 · Posted in Potential Treatments · Comment 

antivirals treat chronic fatigue

Chronic fatigue syndrome, or Systemic Exertion Intolerance Disease (SEID), as it is now known, is characterized by extreme fatigue that cannot be explained by any underlying illness. Doctors have long disagreed over how it should be treated, particularly about whether or not exercise should be encouraged. A new small study of adolescents suggests that anti-viral medications can reduce fatigue.

The 2014 article by Theodore A. Henderson in Advanced Mind Body Medicine reports that among 15 adolescents who reported chronic fatigue symptoms, 1000 mg/day of the antiviral valacyclovir (trade name Valtrex) led to improvement in 86% of the patients by 3 months, and 92% of the patients by 5 months. One patient dropped out due to nausea. Symptoms of fatigue, exertion-induced malaise, excessive sleep, napping, unrefreshing sleep, headaches, cognitive symptoms, and emotional symptoms all improved after treatment with the antiviral. Several previous studies have also shown positive effects of antiviral treatments in patients with chronic fatigue.

Chemicals in E-Cigarettes (Even Nicotine-Free Ones) Cause Cell Damage

April 26, 2016 · Posted in Risk Factors · Comment 

e-cigarettes cause cell damage

E-cigarettes are not regulated to the same extent that cigarettes are by the US Food and Drug Administration, so their contents remain a bit of a mystery. A 2016 study by Vicky Yu and colleagues in Oral Oncology determined that even e-cigarettes without nicotine cause cell damage.

The researchers created an extract from two different brands of e-cigarettes. When they added the extract to human cells in a Petri dish, the cells showed signs of damage (including broken DNA strands) and death compared to untreated cells.

The researchers tested e-cigarettes both with and without nicotine, and those that contained nicotine showed even more signs of cell damage and death after exposure to the contents of the e-cigarette.

Other ingredients that have been identified in e-cigarettes include formaldehyde, which is known to be a carcinogen, and diacetyl, a flavoring agent.

Yu and colleagues suggest that e-cigarettes are not as safe as their marketing would suggest. The researchers hope to identify more of the ingredients in e-cigarettes.

Depression and Resilience Linked to Norepinephrine

April 25, 2016 · Posted in Neurobiology, Neurochemistry · Comment 

resilience related to norepinephrine

Scientists have known for some time that heightened activity of dopaminergic neurons (neurons in the midbrain that contain the neurotransmitter dopamine) can make people vulnerable to depression. New research in animals suggests for the first time that noradrenergic neurons (those that contain the neurotransmitter norepinephrine) control the activity of dopaminergic neurons and that these noradrenergic neurons can make the difference between vulnerability to depression or resilience to stress. The research, published by Elsa Isingrini and colleagues in the journal Nature Neuroscience in 2015, showed that animals that cannot release norepinephrine are vulnerable to depression following chronic stress, but increasing the production of norepinephrine increases the animals’ resilience and reduces depression.

These findings may open up new avenues to treatment that target norepinephrine rather than or in addition to dopamine or serotonin, which is targeted by SSRI antidepressants, or selective serotonin reuptake inhibitors.

More Evidence that Statins Can Reduce Depression in People with Acute Coronary Syndrome

April 22, 2016 · Posted in Potential Treatments · Comment 

statins improve depression

Many studies have linked depression and cardiovascular problems. The solutions may also be linked. A new study found that patients with depression and acute coronary syndrome saw their depression improve most when they took the selective-serotonin reuptake inhibitor (SSRI) antidepressant escitalopram and statins (used to lower cholesterol), while depression improved least among patients who took neither type of drug. Statin use was linked to improvement in depression after one year, while escitalopram was not. In a subset of the study, use of lipophilic statins in particular was linked to improvement in depression.

The study, published in 2015 by S.W. Kim and colleagues in the journal Translational Psychiatry, suggests that statins can improve depression regardless of antidepressant use, but combining statins with an SSRI may have an even more powerful effect on depression.

Next Page »